NO20035434D0 - Behandling eller profylakse av transplantasjonsavst degree tning av insulinproduserende celler - Google Patents

Behandling eller profylakse av transplantasjonsavst degree tning av insulinproduserende celler

Info

Publication number
NO20035434D0
NO20035434D0 NO20035434A NO20035434A NO20035434D0 NO 20035434 D0 NO20035434 D0 NO 20035434D0 NO 20035434 A NO20035434 A NO 20035434A NO 20035434 A NO20035434 A NO 20035434A NO 20035434 D0 NO20035434 D0 NO 20035434D0
Authority
NO
Norway
Prior art keywords
insulin
prophylaxis
treatment
producing cells
transplant rejection
Prior art date
Application number
NO20035434A
Other languages
English (en)
Norwegian (no)
Inventor
Philip Lake
Claudy Mullon
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20035434D0 publication Critical patent/NO20035434D0/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
NO20035434A 2001-06-08 2003-12-05 Behandling eller profylakse av transplantasjonsavst degree tning av insulinproduserende celler NO20035434D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29706901P 2001-06-08 2001-06-08
PCT/EP2002/006278 WO2002100148A2 (en) 2001-06-08 2002-06-07 Treatment or prophylaxis of insulin-producing cell graft rejection

Publications (1)

Publication Number Publication Date
NO20035434D0 true NO20035434D0 (no) 2003-12-05

Family

ID=23144725

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20035434A NO20035434D0 (no) 2001-06-08 2003-12-05 Behandling eller profylakse av transplantasjonsavst degree tning av insulinproduserende celler

Country Status (18)

Country Link
US (5) US20030003099A1 (pt)
EP (1) EP1429845B1 (pt)
JP (1) JP4476623B2 (pt)
CN (1) CN1524002A (pt)
AT (1) ATE424893T1 (pt)
AU (1) AU2002320828B2 (pt)
BR (1) BR0209319A (pt)
CA (1) CA2445605A1 (pt)
DE (1) DE60231522D1 (pt)
ES (1) ES2322442T3 (pt)
IL (1) IL158384A0 (pt)
NO (1) NO20035434D0 (pt)
NZ (1) NZ529044A (pt)
PL (1) PL364359A1 (pt)
PT (1) PT1429845E (pt)
RU (1) RU2003136730A (pt)
WO (1) WO2002100148A2 (pt)
ZA (1) ZA200307893B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE335475T1 (de) * 2001-02-22 2006-09-15 Novartis Pharma Gmbh Verwendung von beschleunigten lymphozyten zielansteuernden wirkstoffen zur herstellung eines medikaments für die behandlung der verzögertern transplantat-funktion
PL1755674T3 (pl) * 2004-05-14 2015-05-29 Alexion Pharma Inc Wydłużanie przeżycia alloprzeszczepu poprzez inhibowanie aktywności dopełniacza
RU2396982C2 (ru) 2004-07-16 2010-08-20 Киорин Фармасьютикал Ко., Лтд. Эффективный способ использования лекарственных средств и способ предотвращения выраженности побочных эффектов
SG158096A1 (en) * 2004-11-29 2010-01-29 Novartis Ag Dosage regimen of an s1p receptor agonist
KR20070102538A (ko) * 2005-02-08 2007-10-18 노파르티스 아게 S1p 수용체 효능제/조절제와 면역억제성 약물의 조합에의한 항림프구 항체 유도
US8778327B2 (en) * 2005-05-11 2014-07-15 Loma Linda University Substances, compositions and methods for preventing and treating immune-mediated inflammatory disorders
WO2009114735A1 (en) * 2008-03-12 2009-09-17 Loma Linda University Dna vaccines and methods for the prevention of transplantation rejection
US20090191218A1 (en) 2005-05-11 2009-07-30 Fengchun Li DNA Vaccines And Methods For The Prevention Of Transplantation Rejection
KR101346527B1 (ko) 2005-12-15 2013-12-31 미쓰비시 타나베 파마 코퍼레이션 아민 화합물 및 그 의약 용도
JP5722524B2 (ja) * 2006-03-02 2015-05-20 アレクシオン ファーマシューティカルズ, インコーポレイテッド 補体活性を抑制することによる同種移植片の生存の延長
ES2537406T3 (es) * 2006-09-28 2015-06-08 Loma Linda University Transfección mediada por células apoptóticas de células de mamífero con ARN de interferencia
WO2009099174A1 (ja) 2008-02-07 2009-08-13 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
AR070842A1 (es) 2008-03-17 2010-05-05 Actelion Pharmaceuticals Ltd Regimen de dosificacion para un agonista de receptor selectivo de s1p1
WO2010055027A2 (en) * 2008-11-11 2010-05-20 Novartis Ag Organic compounds
US8530522B2 (en) * 2008-11-11 2013-09-10 Novartis Ag Organic compounds
BRPI1015133A2 (pt) * 2009-06-30 2016-04-19 Lifescan Scotland Ltd sistemas para o gerenciamento de diabetes e métodos
CN102481101A (zh) * 2009-06-30 2012-05-30 生命扫描有限公司 用于计算基础胰岛素治疗的被分析物测试方法和设备
WO2011041007A1 (en) * 2009-09-29 2011-04-07 Lifescan Scotland Limited Analyte testing method and device for diabetes management
BR112012021572A2 (pt) * 2010-02-25 2016-10-25 Lifescan Scotland Ltd método e sistema de teste de análito com notificação de tendências de glicose sanguínea altas e baixas.
US11680273B2 (en) 2011-09-23 2023-06-20 Loma Linda University Treatment of autoimmune diseases
DK2758074T3 (da) 2011-09-23 2020-07-27 Univ Loma Linda Bakteriestammer der udtrykker methylasegener og anvendelser deraf
CN114306643A (zh) * 2021-11-30 2022-04-12 中国科学院昆明动物研究所 一种恒河猴免疫抑制模型的构建方法及在car-t细胞植活上的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0627406T3 (da) * 1992-10-21 1999-07-12 Taito Co 2-Amino-1,3-propandiolforbindelser og immunundertrykkende midler
US5679546A (en) * 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
EP0750458B1 (en) * 1994-03-03 2003-08-27 Alexion Pharmaceuticals, Inc. Terminal complement inhibitor fusion genes and proteins
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
ATE335475T1 (de) * 2001-02-22 2006-09-15 Novartis Pharma Gmbh Verwendung von beschleunigten lymphozyten zielansteuernden wirkstoffen zur herstellung eines medikaments für die behandlung der verzögertern transplantat-funktion

Also Published As

Publication number Publication date
RU2003136730A (ru) 2005-05-20
EP1429845A2 (en) 2004-06-23
BR0209319A (pt) 2004-07-20
ZA200307893B (en) 2004-09-06
WO2002100148A3 (en) 2004-04-22
EP1429845B1 (en) 2009-03-11
JP4476623B2 (ja) 2010-06-09
JP2004534788A (ja) 2004-11-18
ATE424893T1 (de) 2009-03-15
CN1524002A (zh) 2004-08-25
NZ529044A (en) 2008-03-28
DE60231522D1 (de) 2009-04-23
WO2002100148A2 (en) 2002-12-19
US20060153842A1 (en) 2006-07-13
US20080199465A1 (en) 2008-08-21
US20110236382A1 (en) 2011-09-29
PT1429845E (pt) 2009-06-15
CA2445605A1 (en) 2002-12-19
IL158384A0 (en) 2004-05-12
US20030003099A1 (en) 2003-01-02
ES2322442T3 (es) 2009-06-22
US20140093502A1 (en) 2014-04-03
AU2002320828B2 (en) 2006-02-02
PL364359A1 (en) 2004-12-13

Similar Documents

Publication Publication Date Title
NO20035434D0 (no) Behandling eller profylakse av transplantasjonsavst degree tning av insulinproduserende celler
ES2178036T3 (es) Derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que le contienen.
ES2095813B1 (es) Protesis de deslizamiento para rodilla.
ES2173948T3 (es) Mezclas de 2',3'-didesoxi-inosina e hidrocarbamida para la inhibicion de la propagacion retroviral.
DK0948527T3 (da) Cylosporinderivater, fremstilling af disse og farmaceutiske præparater indeholdende disse
DE69435137D1 (de) Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
DE60019116D1 (de) Neue omeprazole und (s)-omeprazole zusammensetzung
PT951474E (pt) Novos derivados da ciclosporina sua preparacao e composicoes farmaceuticas que os contem
TNSN00010A1 (fr) DIPHENYLUREE A SUBSTITUTION ω CARBOXYARYLE SERVANT D'INHIBUTEURS DE RAF KINASE.
DE69108048T2 (de) Derivate von hydroxaminsäure und von n-hydroxyharnstoff sowie ihre verwendung.
AR024138A1 (es) Inhibidores de la proliferacion celular
NO20022557L (no) 2,4-diaminopyrimidinforbindelser nyttige som immunosuppreserende midler
DE69919179D1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
CA2162587A1 (en) Therapeutic inhibitor of vascular smooth muscle cells
WO2001078653A3 (en) Graft rejection inhibition with ccr2 inhibitors
TR200101704T2 (tr) Transplant reddinin engellenmesi için bir MEK inhibitörünün kullanımı
NZ330944A (en) Peptide derivatives
PT1223971E (pt) Composicoes e metodos para prevencao e tratamento da rejeicao de transplante
EP1065200A4 (en) Aminoisoquinoline DERIVATIVES
DK0561882T3 (da) Hydroxamsyrederivater, som inhiberer lipoxygenase
NO20011371L (no) Kjemokinreseptorantagonist og cyklosporin i kombinert terapi
ES2153584T3 (es) Piridiniminil-1,2-benzisoxazol y -benzisotiazol como antipsicoticos.
WO2001056551A3 (en) Method and formulation for treatment of vasoconstriction
EP0326067A3 (en) Use of cyclophilin as an anti-inflammatory and immunomodulatory agent
HRP20040165B1 (en) Citalopram for the treatment of elevated blood pressure

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application